Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016

Jiangmei Liu1†, Weiping Liu2†, Lan Mi2, Xinying Zeng1, Cai Cai3, Jun Ma4*, Lijun Wang1*, Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology and Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology

Abstract
Background: The accurate information about burden of multiple myeloma (MM) at national and provincial level remains unknown in China.

Methods: Following the general analytical strategy used in GBD 2016, the age-, sex-, and province-specific incidence and mortality in China were analyzed. Trends in the incidence and mortality from 2006 to 2016 were evaluated.

Results: It was estimated that there were 16,500 new cases and 10,300 deaths of multiple myeloma in China in 2016. The age-standardized incidence rates (ASIR) and mortality rates (ASMR) per 100,000 population were 1.03 (95% UI, 0.88–1.17) and 0.67 (95% UI, 0.59–0.77) in 2016. Males had higher incidence and mortality rates than females in all age groups. An upward trend with age in incidence and mortality was observed. Higher incidence and mortality rates clustered in the developed provinces. The incidence of MM in China increased significantly from 2006 to 2016, while the mortality increased from 2006 to 2014, and remained stable from 2014 to 2016.

Conclusion: The burden of MM showed a heterogeneous pattern in China, which highlighted the need of tailored disease prevention and control strategies in both national and provincial levels.

Keywords: Multiple myeloma, Incidence, Mortality, Epidemiology

Background
Multiple myeloma (MM) is the second most frequent hematological disease worldwide [1]. In 2016, the incident cases of MM in the most populous countries were 139,000 with the rank of 26 among all cancers, and death number was 98,000 with the rank of 22 among all cancers [2]. According to the statistics of GLOBOCAN 2018, MM accounted for 0.9% of all new cancer cases and 1.1% of all cancer deaths worldwide in 2018 [3]. A recent study estimated that there were 52,000 deaths associated with lymphoma and myeloma and the age-standardized mortality rate was 3.74 per 100,000 population in China in 2017. While the age-standardized mortality rate for lymphoma and myeloma worldwide was 2.60 per 100,000 population. Moreover, the mortality rates of lymphoma and myeloma increased annually by 4.5% from 2004 to 2016 in China [4].

Until now, accurate epidemiologic study of MM based on national and province level has not been conducted in China. In this analysis, we sought to determine the incidence and mortality of multiple myeloma in China in 2016 and analyze temporal trends from 2006 to 2016.

Methods
Data sources
Details of the methodology used in the Global Burden of Disease 2016 (GBD 2016) study have been explained in previous studies [5–7]. Briefly, the GBD study provides a...
highly standardized approach to dealing with the multiple measurement challenges in the cause of death assessment and provided a comprehensive assessment of age-specific, sex-specific, all-cause, and cause-specific mortality rates for all major diseases and injuries for 195 countries and territories from 1980 to 2016. The present study focused on the burden of multiple myeloma nationally and 33 province-level administrative units in China, including Hong Kong and Macao Special Administrative Regions, all of which we refer to as provinces in this study. International Classification of Diseases-10 (ICD-10) codes were used to represent multiple myeloma (C88-C90.32).

The main data sources GBD used for multiple myeloma mortality estimates come from the disease surveillance points system and the cause of death reporting system from Chinese Center for Disease Control and Prevention. All data sources that were used in GBD study were mapped to the GBD standard GBD ICD-10 cause list [5]. The underreporting adjustment and garbage code redistribution were applied for more accurate estimates of multiple myeloma mortality. In GBD 2016, causes that cannot be underlying causes of death (termed garbage codes) are reassigned to causes that can be underlying causes of death. According to the regional variations of data quality across county, different underreporting rates were used to adjust the estimation of mortality. We used the GBD 2016 standard population for computing age-standardized rates. We generated a 95% uncertainty interval (UI) for all quantities reported in the article.

For GBD 2016, we used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between incidence, prevalence, remission, and cause of death rates for each condition. We used a compartmental model structure with a series of differential equations that synthesize spares and heterogeneous epidemiological data, including systematic reviews, gray literature sources, and survey data. Detailed descriptions of the modeling strategy for incidence estimation and validation have been published elsewhere [7]. The number of incidence and age-standardized incidence rate of multiple myeloma and 95% UI were reported.

Statistical analysis
Temporal trends in incidence and mortality rates from 2006 to 2016 were examined by IBM SPSS Statistics for Windows (Version 21.0; IBM Corp) and fitting joinpoint models (version 4.6.0.0; National Cancer Institute). The trends were expressed as annual percentage changes (APCs), and Z tests were used to assess whether the APCs were significantly different from zero. In describing trends, the terms “increase” and “decrease” would be used when the slope of the trend was statistically significant; otherwise, the term “stable” was used. Statistical significance was assessed at the 0.05 level, and all hypothesis tests were two-sided.

Results
Incidence and mortality of multiple myeloma in China, 2016
It was estimated that there were 16,500 new cases and 10,300 deaths of multiple myeloma in China in 2016. The age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASMR) per 100,000 population were 1.03 (95% UI, 0.88–1.17) and 0.67 (95% UI, 0.59–0.77) in 2016. After the age of 15 years, the incidence and mortality rates increased steadily with age, and higher incidence and mortality rates of multiple myeloma were seen in the individuals over 60 years (Table 1, Fig. 1). Both ASIR and ASMR had an upward trend with age, and the peak occurred at the age group of 90–94 years. In addition, 1.5–2-folds sex-specific difference of ASIR and ASMR was observed; males were consistently higher than females.

Provincial-level incidence and mortality of multiple myeloma in 2016
Table 2 and Fig. 2 show the incidence and mortality for each of the 33 provinces in 2016. The ASIR were highest in Hong Kong Special Administrative Region, Macao Special Administrative region, and Shanghai, and were lowest in Gansu, Hainan, and Yunnan, respectively. The ASMR were highest in Hong Kong Special Administrative Region, Zhejiang, and Shanghai, and were lowest in Hainan, Fujian, and Shandong, respectively.

Trends in incidence and mortality of multiple myeloma from 2006 to 2016
As shown in Fig. 3, the ASIR of multiple myeloma increased significantly with an APC of 3.28 from 2006 to 2014 and 2.32 from 2014 to 2016. On the other hand, the ASMR increased from 2006 to 2014 with an APC of 0.78 and remained stable from 2014 to 2016 with an APC of 0.34.

Discussion
The present study is the most comprehensive evaluation of the large and ever-growing burden of multiple myeloma in China. Due to the standardized methods for estimates of multiple myeloma metrics used in the GBD study, it is possible to compare incidence and mortality at province level in China. Based on the disparities in disease burden, different strategies for disease prevention and control should be employed when health policy is developed in the future.
### Table 1 Incidence and mortality rates of multiple myeloma by age and gender in 2016 (per 100,000 population)

| Age groups | Incidence rates | Mortality rates |
|------------|----------------|-----------------|
|            | Both | Male | Female | Both | Male | Female |
| 0-         | 0.00 | 0.00 | 0.00    | 0.00 | 0.00 | 0.00    |
| 1-         | 0.00 | 0.00 | 0.00    | 0.00 | 0.00 | 0.00    |
| 5-         | 0.00 | 0.00 | 0.00    | 0.00 | 0.00 | 0.00    |
| 10-        | 0.00 | 0.00 | 0.00    | 0.00 | 0.00 | 0.00    |
| 15-        | 0.18 (0.11–0.22) | 0.24 (0.12–0.30) | 0.12 (0.07–0.14) | 0.09 (0.05–0.10) | 0.11 (0.06–0.13) | 0.06 (0.04–0.07) |
| 20-        | 0.22 (0.14–0.26) | 0.27 (0.14–0.33) | 0.18 (0.10–0.22) | 0.09 (0.06–0.11) | 0.10 (0.05–0.12) | 0.08 (0.05–0.10) |
| 25-        | 0.29 (0.18–0.34) | 0.39 (0.21–0.47) | 0.18 (0.11–0.22) | 0.10 (0.06–0.11) | 0.12 (0.07–0.14) | 0.07 (0.04–0.08) |
| 30-        | 0.25 (0.17–0.30) | 0.34 (0.21–0.42) | 0.16 (0.09–0.20) | 0.10 (0.07–0.11) | 0.12 (0.08–0.14) | 0.07 (0.04–0.08) |
| 35-        | 0.31 (0.23–0.37) | 0.42 (0.28–0.52) | 0.20 (0.12–0.24) | 0.14 (0.11–0.15) | 0.17 (0.12–0.21) | 0.10 (0.07–0.12) |
| 40-        | 0.51 (0.41–0.59) | 0.66 (0.48–0.79) | 0.36 (0.24–0.44) | 0.26 (0.21–0.29) | 0.31 (0.24–0.38) | 0.20 (0.14–0.25) |
| 45-        | 0.87 (0.70–0.97) | 1.08 (0.79–1.33) | 0.64 (0.47–0.75) | 0.44 (0.37–0.49) | 0.51 (0.39–0.64) | 0.37 (0.27–0.43) |
| 50-        | 1.71 (1.44–1.99) | 2.08 (1.56–2.67) | 1.32 (0.99–1.64) | 0.88 (0.77–1.02) | 0.99 (0.77–1.27) | 0.76 (0.57–0.92) |
| 55-        | 2.44 (2.03–2.96) | 3.15 (2.33–4.00) | 1.71 (1.36–2.19) | 1.33 (1.14–1.59) | 1.62 (1.23–2.08) | 1.04 (0.84–1.33) |
| 60-        | 3.62 (3.00–4.28) | 4.63 (3.36–5.77) | 2.60 (2.08–3.17) | 2.19 (1.87–2.59) | 2.60 (1.96–3.36) | 1.77 (1.45–2.15) |
| 65-        | 4.60 (3.92–5.47) | 5.68 (4.25–7.20) | 3.53 (2.88–4.54) | 3.11 (2.71–3.75) | 3.52 (2.74–4.58) | 2.71 (2.22–3.44) |
| 70-        | 5.36 (4.42–6.29) | 7.00 (5.16–8.67) | 3.76 (3.00–5.03) | 3.83 (3.27–4.50) | 4.63 (3.58–5.81) | 3.05 (2.44–4.06) |
| 75-        | 5.71 (4.63–6.57) | 7.62 (5.48–9.40) | 3.96 (3.20–4.92) | 4.45 (3.67–5.18) | 5.40 (4.03–7.02) | 3.58 (2.91–4.45) |
| 80-        | 4.01 (3.30–4.66) | 5.43 (3.83–6.77) | 2.79 (2.27–3.45) | 4.11 (3.45–4.91) | 5.39 (3.97–6.92) | 3.01 (2.42–3.73) |
| 85-        | 4.65 (3.94–5.70) | 6.37 (4.72–8.53) | 3.50 (2.95–4.40) | 4.68 (4.03–5.79) | 6.14 (4.70–8.38) | 3.69 (3.05–4.60) |
| 90-        | 7.07 (6.31–8.83) | 9.18 (7.34–13.02) | 6.03 (5.21–7.70) | 6.96 (6.20–8.80) | 8.56 (7.00–12.29) | 6.17 (5.30–7.75) |
| 95-        | 6.43 (5.70–8.43) | 9.14 (7.59–13.33) | 5.48 (4.74–7.26) | 6.38 (5.62–8.42) | 8.50 (7.16–12.70) | 5.65 (4.88–7.49) |

Data in parentheses are 95% uncertainty intervals

**Fig. 1** Age-specific incidence and mortality rates of multiple myeloma by sex in China, 2016
The patterns of burden of MM varied by age and sex. Unlike most other cancers in China, MM was rare between 0–14 years old. Both incidence and mortality rate were increased with age in most of the age groups, which was consistent with previous study published by our group [4]. Notably, male predominance of incidence and mortality was seen in all age groups. According to the GBD study, both the age-standardized incidence and mortality rate in China were lower than global (ASIR was 1.93 per 100,000 population with 95% UI 1.87–2.19, ASMR was 1.37 per 100,000 population with 95% UI 1.26–1.52) and our neighbor Japan (ASIR was 2.18 per 100,000 population with 95% UI 1.91–2.78, ASMR was 1.30 per 100,000 population with 95% UI 1.17–1.58) [5, 7]. Geographical differences across provinces had an important role in the epidemiological characteristics of MM in China. Overall, higher incidence and mortality rates were seen in the clustered developed provinces, with 2–3-fold gap between those developed and less-developed provinces. In addition, the incidence level in

**Table 2 Incidence and mortality of multiple myeloma by province of China in 2016**

|                | Incidence                          | Mortality                          |
|----------------|------------------------------------|------------------------------------|
|                | Cases (thousands) | Rates (per 100,000) | Deaths (thousands) | Rates (per 100,000) |
| Anhui          | 0.53 (0.46–0.61) | 0.75 (0.65–0.86) | 0.43 (0.37–0.51) | 0.62 (0.53–0.73) |
| Beijing        | 0.47 (0.30–0.56) | 1.78 (1.12–2.11) | 0.21 (0.13–0.26) | 0.85 (0.55–1.05) |
| Chongqing      | 0.32 (0.29–0.39) | 0.84 (0.75–1.00) | 0.24 (0.20–0.30) | 0.63 (0.53–0.77) |
| Fujian         | 0.33 (0.28–0.41) | 0.82 (0.71–1.04) | 0.21 (0.18–0.28) | 0.55 (0.46–0.73) |
| Gansu          | 0.19 (0.17–0.23) | 0.69 (0.59–0.80) | 0.16 (0.14–0.20) | 0.60 (0.51–0.72) |
| Guangdong      | 1.47 (1.10–1.73) | 1.40 (1.06–1.62) | 0.67 (0.53–0.79) | 0.69 (0.55–0.81) |
| Guangxi        | 0.45 (0.39–0.54) | 0.88 (0.76–1.05) | 0.34 (0.28–0.42) | 0.67 (0.57–0.84) |
| Guizhou        | 0.28 (0.23–0.31) | 0.75 (0.62–0.83) | 0.26 (0.21–0.31) | 0.70 (0.59–0.83) |
| Hainan         | 0.07 (0.05–0.09) | 0.73 (0.63–1.02) | 0.05 (0.04–0.07) | 0.53 (0.43–0.76) |
| Hebei          | 0.74 (0.62–1.09) | 0.85 (0.73–1.27) | 0.48 (0.39–0.69) | 0.58 (0.47–0.84) |
| Heilongjiang   | 0.45 (0.40–0.60) | 0.89 (0.78–1.18) | 0.31 (0.27–0.41) | 0.64 (0.55–0.83) |
| Henan          | 0.87 (0.75–1.19) | 0.86 (0.75–1.18) | 0.60 (0.51–0.82) | 0.62 (0.53–0.83) |
| Hubei          | 0.79 (0.67–0.93) | 1.12 (0.96–1.31) | 0.44 (0.37–0.52) | 0.65 (0.55–0.78) |
| Hunan          | 0.82 (0.61–0.93) | 1.03 (0.77–1.16) | 0.60 (0.47–0.70) | 0.77 (0.59–0.88) |
| Inner Mongolia | 0.27 (0.24–0.36) | 0.92 (0.80–1.22) | 0.17 (0.14–0.23) | 0.62 (0.52–0.82) |
| Jiangsu        | 1.33 (1.15–1.64) | 1.26 (1.10–1.55) | 0.59 (0.50–0.74) | 0.58 (0.49–0.72) |
| Jiangxi        | 0.46 (0.28–0.53) | 0.98 (0.61–1.13) | 0.36 (0.24–0.43) | 0.80 (0.52–0.95) |
| Jilin          | 0.33 (0.28–0.42) | 0.91 (0.80–1.18) | 0.22 (0.19–0.27) | 0.64 (0.55–0.80) |
| Liaoning       | 0.66 (0.58–0.80) | 1.05 (0.91–1.24) | 0.41 (0.34–0.50) | 0.66 (0.56–0.81) |
| Ningxia        | 0.05 (0.04–0.06) | 0.79 (0.69–0.91) | 0.04 (0.03–0.05) | 0.65 (0.55–0.77) |
| Qinghai        | 0.05 (0.04–0.06) | 0.87 (0.74–1.04) | 0.04 (0.03–0.05) | 0.75 (0.63–0.92) |
| Shaanxi        | 0.37 (0.33–0.44) | 0.84 (0.74–1.00) | 0.27 (0.23–0.33) | 0.63 (0.53–0.78) |
| Shandong       | 1.08 (0.91–1.59) | 0.88 (0.74–1.29) | 0.67 (0.55–0.96) | 0.56 (0.46–0.81) |
| Shanghai       | 0.63 (0.31–0.79) | 1.89 (0.90–2.35) | 0.30 (0.16–0.39) | 0.95 (0.48–1.22) |
| Shanxi         | 0.33 (0.28–0.44) | 0.81 (0.70–1.11) | 0.22 (0.18–0.31) | 0.58 (0.48–0.80) |
| Sichuan        | 0.89 (0.77–1.01) | 0.86 (0.75–0.97) | 0.69 (0.59–0.85) | 0.67 (0.57–0.82) |
| Tianjin        | 0.24 (0.20–0.31) | 1.39 (1.18–1.79) | 0.11 (0.09–0.14) | 0.67 (0.56–0.85) |
| Tibet          | 0.02 (0.01–0.02) | 0.81 (0.64–0.91) | 0.02 (0.01–0.02) | 0.80 (0.64–0.93) |
| Xinjiang       | 0.22 (0.19–0.30) | 1.01 (0.88–1.39) | 0.15 (0.13–0.21) | 0.75 (0.64–1.02) |
| Yunnan         | 0.34 (0.31–0.41) | 0.74 (0.67–0.87) | 0.29 (0.25–0.37) | 0.64 (0.55–0.81) |
| Zhejiang       | 1.22 (0.58–1.53) | 1.76 (0.82–2.20) | 0.67 (0.32–0.85) | 1.01 (0.48–1.29) |
| Hong Kong*     | 0.27 (0.13–0.33) | 2.31 (1.15–2.87) | 0.13 (0.06–0.16) | 1.07 (0.55–1.35) |
| Macao*         | 0.01 (0.01–0.02) | 2.06 (1.18–2.80) | 0.01 (0.00–0.01) | 0.99 (0.57–1.31) |

Data in parentheses are 95% uncertainty intervals

*Special Administrative Regions
the developed provinces was more close to those developed countries in Asia, like Japan. The low incidence and mortality rates in less-developed provinces may be associated with the poor medical accessibility. The heterogeneous pattern of epidemiological characteristics of MM across provinces highlighted the need to improve the access to health services leading to more precise diagnosis and early treatment, especially in those less-developed provinces.

Improving diagnosis and treatment techniques had a positive effect on the mortality of MM. The result of EUROCARE-5 [8] reflected the encouraging trend of
MM and plasmacytoma with survival increase from 29.8% in 1997–1999 to 39.6% in 2006–2008. High-dose chemotherapy followed by autologous hematopoietic cell transplantation changed dramatically the perspective for young patients, while novel agents such as bortezomib, thalidomide, and lenalidomide prolonged the survival for both young and elderly patients [1]. Real-world study from the Swedish Myeloma Registry showed that the 5-year relative survival increased from 47.3% in the period of 2008–2010 to 51.3% in the period of 2011–2015 with the increased use of novel agents [9]. Another study from the Swedish Cancer Register also showed that the 10-year mortality in patients younger than 60 years in 1994–2003 reduced 29% compared with that in 1987–1993 [10]. A study from the Asian Myeloma Network, involving 3405 symptomatic MM patients, demonstrated that the median overall survival was 47 months (95% CI 44.0–50.0) and better survival was observed in those treated with stem cell transplantation or new drugs [11]. In a multicenter study [12] including 940 newly diagnosed MM patients from China, the median overall survival (OS) was 54 months with more survival benefit in IgG patients receiving bortezomib. Notably, the Food and Drug Administration of China approved bortezomib in 2005 and lenalidomide in 2013 for the treatment of MM. Until then, the Chinese patients had a chance of being exposed to novel drugs because they received treatment with many clinical trials in tertiary hospitals [11]. In our study, the mortality of MM increased from 2006 to 2014, but remained stable since 2014, regardless of the continuous increasing incidence. Similarly, a systematic analysis for global burden of MM [13] demonstrated that there was an improvement in age-standardized death rate form 1990 to 2016 in high-income sociodemographic index regions despite increasing incidence rates, which indicated that patients with MM, especially in developed areas, benefited from treatment advancement. All these findings suggested modern risk-adaptive therapies brought longer survival for MM patients and then led to decrease of mortality of MM. There are marked differences in the epidemiological characteristics of MM between western and eastern countries. Increasing incidence trends were verified for most of the European and American countries, which was attributed to better accessibility to health services and more precise diagnosis of MM [14]. In Great Britain, the MM age-adjusted incidence per100,000 increased from 3.2 in 1975–1979 to 5.4 in 2005–2009. In addition, the data in this study argued strongly against the notion that environmental exposures were responsible for the changes in incidence [15]. In the USA, the incidence rates of MM per 100,000 remained stable over the three decades, with 4.6 in 1981–1990, 4.7 in 1991–2000, and 4.7 in 2001–2010, respectively [16]. In our study, we determined that the burden of MM was increasing in China during the past decade. This upward trend of incidence may be explained partly by some factors such as aging, better access to diagnosis, excess body weight [17], and occupational exposures [18], but much of this trend was largely unexplained and further study focused on etiology of MM should be performed.

The interpretation of our study has several limitations. First, all the general limitations described by the GBD collaboration group [5–7, 19] apply to the present study. Second, the low incidence and mortality rates of MM both in the national level and in the province levels may bias the estimated results using the standard GBD methodology. Third, population growth and changes of socioeconomic structures should also be taken into account; the spatial-temporal trends of MM burden needs to be interpreted cautiously.

Conclusions
This is the first study to present spatiotemporal variation in MM burden in China nationally. Higher incidence and mortality rates were observed in males and older individuals with geographical differences across provinces. A significant increase in the incidence of MM was notable. The study results will be useful for policy-making with respect to disease prevention and the development of management strategies.

Abbreviations
APCs: Annual percentage changes; ASIR: Age-standardized incidence rates; ASMR: Age-standardized mortality rates; GBD: Global burden of disease; ICD: International classification of diseases; MM: Multiple myeloma; OS: Overall survival; UI: Uncertainty interval

Acknowledgements
We thank Dr. Lei Yang and Dingyao Xu from Peking University Cancer Hospital & Institute for their useful comments and language editing which have greatly improved the manuscript.

Authors’ contributions
JL and WL conceived and designed the study, analyzed the data, and drafted and revised the paper. LM, XZ, and CC prepared and analyzed the data. XZ drafted and revised the paper. JM and LW designed the study, interpreted the results, and drafted and revised the paper. All authors provided critical comments on the manuscript. All authors read and approved the final manuscript.

Funding
This research was supported by the China Special Program for Basic Research 2014 from Ministry of Science and Technology (grant no. 2014FY111100). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

Availability of data and materials
The data that support the findings of this study are available from the Chinese Center for Disease Control and Prevention, but restrictions apply to the availability of these data, which were used under license for the current study, and thus are not publicly available. However, data are available from the authors upon reasonable request and with permission from the Chinese Center for Disease Control and Prevention.

Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. 2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China. 3 Beijing Institute of Survey and Mapping, Beijing Municipal Key Laboratory of Urban Spatial Information Engineering, Beijing, China. 4 Harbin Institute of Hematology & Oncology, Harbin, China. Municipal Key Laboratory of Urban Spatial Information Engineering, Beijing, China. 2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. 9. Blimark CH, Turesson I, Genell A, et al. Outcome and survival of myeloma patients diagnosed patient. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):498–507.

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4(11):1553–68.

3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

4. Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol. 2019;12(1):22.

5. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–210.

6. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1260–344.

7. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.

8. Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931–42.

9. Blimark CH, Turesson I, Genell A, et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish myeloma registry. Haematologica. 2018;103(4):507.

10. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993–9.

11. Kim K, Lee JH, Kim JS, et al. Clinical profiles of multiple myeloma in Asia-an Asian myeloma network study. Am J Hematol. 2014;89(7):751–6.

12. Lu J, Lu J, Chen W, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4:e239.

13. Cowan AJ, Allen C, Barac A, Basaleem H, Bensonor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–7.

14. Curado MP, Oliveira MM, Silva DRM, et al. Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med. 2018;7(5):2101–8.

15. Vélez R, Turesson I, Landgren O, et al. Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends. BMJ Open. 2016;6(1):e009584.

16. Sun T, Wang S, Sun H, et al. Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades. Leuk Lymphoma. 2018;59(1):49–58.

17. Sung H, Siegel RL, Torre LA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2019;69(2):88–112.

18. Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.

19. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1345–422.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.